Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives $7.25 Consensus Target Price from Analysts

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) have been assigned an average rating of “Moderate Buy” from the seven analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $7.25.

A number of analysts have commented on PSTV shares. HC Wainwright reaffirmed a “buy” rating and set a $2.00 price target on shares of Plus Therapeutics in a research report on Wednesday, November 26th. Ascendiant Capital Markets decreased their target price on Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating for the company in a report on Friday, November 21st. Zacks Research downgraded shares of Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Wednesday, October 8th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Plus Therapeutics in a report on Thursday, January 8th.

Plus Therapeutics Trading Up 2.3%

NASDAQ:PSTV opened at $0.29 on Thursday. Plus Therapeutics has a twelve month low of $0.16 and a twelve month high of $2.31. The company has a market cap of $40.53 million, a PE ratio of -0.15 and a beta of 0.85. The company’s 50 day moving average is $0.54 and its two-hundred day moving average is $0.54.

Plus Therapeutics (NASDAQ:PSTV) last posted its quarterly earnings data on Thursday, October 30th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The firm had revenue of $1.40 million for the quarter, compared to analyst estimates of $1.50 million. As a group, analysts expect that Plus Therapeutics will post -2.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Plus Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new stake in Plus Therapeutics during the second quarter worth about $41,000. Susquehanna International Group LLP purchased a new position in shares of Plus Therapeutics during the 3rd quarter valued at approximately $46,000. Scientech Research LLC acquired a new position in shares of Plus Therapeutics in the 3rd quarter valued at $100,000. Finally, Altium Capital Management LLC acquired a new position in shares of Plus Therapeutics in the 3rd quarter valued at $628,000. Hedge funds and other institutional investors own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics is a clinical?stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.